XML 143 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1
Fixed assets
12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Fixed assets

4. Fixed assets

Fixed assets, net were as follows at December 31, 2024 and 2023:

December 31, 

    

2024

    

2023

Leasehold improvements

$

31,531

$

30,166

Computer equipment and software

 

24,043

 

17,503

Machinery and lab equipment

33,304

62,837

Furniture and fixtures

 

2,416

 

3,849

Assets in process

 

3,034

 

24,008

 

94,328

 

138,363

Less accumulated depreciation

 

(33,358)

 

(51,274)

Total

$

60,970

$

87,089

Depreciation expense was approximately $14.9 million, $13.9 million, and $12.3 million for the years ended December 31, 2024, 2023, and 2022, respectively.

During the year end December 31, 2024, the Company recorded a $4.4 million loss primarily related to the sale of certain assets for gene therapy manufacturing. Additionally, in connection with the South Plainfield, New Jersey office closure, as well as the Warren, New Jersey lease modification, the Company recorded a $4.1 million loss primarily related to fixed assets impairments. Both the fixed asset loss on sale and fixed asset impairments are recorded on the Company’s consolidated statement of operations within tangible asset impairment and losses (gains) on transactions, net.